April 7, 2009 - Lantheus Medical Imaging Inc. has acquired the U.S., Canadian and Australian rights to MS-325 (formerly marketed as VASOVIST, gadofosveset trisodium, by Bayer Schering Pharma) from EPIX Pharmaceuticals.

In December 2008, EPIX received FDA marketing approval for the magnetic resonance angiography (MRA) agent MS-325 to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. Currently, there are no other imaging agents approved for MRA in the U.S.

Under the terms of the agreement, Lantheus acquired the U.S. (including Puerto Rico), Canadian, and Australian rights to MS-325 from EPIX. EPIX will continue to own European and other ex-U.S. rights for the imaging agent. Lantheus is planning to launch MS-325 under a different name before the year-end.

MS-325 is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through MRA. MS-325 has been approved for marketing in the U.S. and in 37 countries outside the U.S.

For more information: www.lantheus.com.


Related Content

News | Breast Imaging

July 7, 2025 — SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, has ...

Time July 08, 2025
arrow
News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | PET-CT

June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging ...

Time June 23, 2025
arrow
News | Cardiac Imaging

May 20, 2025 — Royal Philips has launched the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter ...

Time May 27, 2025
arrow
News | Pediatric Imaging

May 13, 2025-- GE HealthCare recently announced the U.S. Food and Drug Administration (FDA) has approved a pediatric ...

Time May 20, 2025
arrow
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiology Imaging

July 23, 2024 — EMVision, an Australian medical device company focused on the development and commercialization of ...

Time July 23, 2024
arrow
Feature | SCCT | by Christine Book

June 27, 2024 — The countdown has begun for the Society of Cardiovascular Computed Tomography (SCCT) 19th Annual ...

Time June 27, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
Subscribe Now